Sift Bio

Sift Bio, based in the US, specializes in immunotherapy solutions that harness advanced technologies, including AI and metagenomics, to develop targeted treatments for cancers and autoimmune diseases. Sift Bio, founded in 2024 in San Carlos, US, focuses on innovating immunotherapy by utilizing a peptide platform that enhances immune responses. The company has successfully closed two deals and secured USD 3. 70 mn in its latest funding round from investors including Eisai Innovation and Freeflow Ventures.

Founder details and prior ventures are not available. Sift Bio offers a proprietary peptide immunotherapy platform that leverages artificial intelligence (AI), metagenomics, and high-throughput T-cell screening to enhance immune responses in patients with cancers and autoimmune diseases. The platform focuses on discovering microbially derived peptides that activate memory T cells capable of recognizing both microbial and cancer targets. Through this innovative approach, Sift aims to provide targeted, effective, and safe treatments where traditional therapies have been inadequate.

The company’s core offerings cater to the oncology and immunology markets, primarily serving biopharmaceutical companies and research institutions engaged in the development of novel immunotherapeutics. Geographically, Sift Bio targets markets in North America, Europe, and Asia, where there is a growing demand for advanced immunotherapy solutions. Sift Bio's revenue model is structured around partnerships and collaborations with biopharmaceutical companies and research institutions that seek to utilize its immunotherapy platform for drug development. Transactions typically involve licensing agreements and collaborative research agreements, where Sift provides its expertise in AI-driven discovery and T-cell screening in exchange for funding and revenue-sharing arrangements.

The company's services are designed to assist clients in progressing their immunotherapy pipelines, often leading to IND-enabling studies. While specific pricing structures for its products and services are not disclosed, partnerships generally entail customized agreements based on the scope of collaboration and research goals, reflecting the specialized nature of Sift’s offerings in the burgeoning field of cancer and autoimmune disease therapeutics. Sift Bio plans to utilize its recent funding to propel the development of its immunotherapy platform, which will include launching new peptide-based products aimed at expanding treatment options for cancer and autoimmune diseases. Additionally, the company is exploring entry into the Asian market by 2025, aligning its strategies with the growing demand for immunotherapy in that region.